Nikiforita Poulakaki

Nikiforita Poulakaki

Auto-generated profile, based on publicly available information

Nikiforita Poulakaki

Department of Breast Surgery, Euroclinic of Athens, Athens, Greece

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2004 in American Heart Journal
Verified
Journal Article
Closed access
KSKimon Stamatelopoulos
Kimon Stamatelopoulos
JLJohn P Lekakis
John P Lekakis
NPNikiforita A Poulakaki
Nikiforita A Poulakaki
CPChristos M Papamichael
Christos M Papamichael
KVKyriaki Venetsanou
Kyriaki Venetsanou
SSStamatios F Stamatelopoulos
Stamatios F Stamatelopoulos

1 January 2006 in Tumori Journal
Verified
Journal Article
Closed access
PDF file
CGConstantine Gennatas
Constantine Gennatas
VMVasiliki Michalaki
Vasiliki Michalaki
ECEleni Carvounis
Eleni Carvounis
JPJohn Psychogios
John Psychogios
NPNikiforita Poulakaki
Nikiforita Poulakaki
NTNikolaos Tsavaris
Nikolaos Tsavaris
Aims and Background: The understanding of hormonal therapies in postmenopausal women with metastatic breast cancer has advanced greatly in the past several decades. With the introduction of orally active, potent and selective third-generation aromatase inhibitors (anastrozole, letrozole and exemestane), approaches to the treatment of hormone-sensitive advanced breast cancer are undergoing reevaluation. For treatment of advanced or metastatic disease that has progressed on tamoxifen, all three agents are active. The purpose of the study was to assess the antitumor efficacy and tolerance of exemestane administered as third-line hormonal therapy to postmenopausal women with metastatic breast cancer refractory to letrozole and anastrozole. Study design: Sixty postmenopausal women with stage IV hormone receptor-positive carcinoma of the breast were enrolled in the study. All patients had received two prior hormonal manipulations and had measurable or assessable disease. All adverse events were monitored. Results: Objective tumor response was achieved in 12 (20%) patients (95% CI, 9.6-30.4). The overall clinical benefit was 38.3% (95% CI, 21.2-49.3), and the median duration of objective tumor response was 20 months (range, 9-26). The median time to death was 17.4 months (95% CI, 16.14-18.66). Conclusions: Exemestane represents an active and well-tolerated treatment option in pretreated patients with advanced breast cancer who have received standard first- and second-line hormonal therapies. By extending the sequence of hormonal therapy, disease progression and the need for chemotherapy may be significantly delayed.

1 January 2017 in Dermatologic Surgery
Verified
Journal Article
Closed access
GMGeorgios-Marios Makris
Georgios-Marios Makris
NPNikiforita Poulakaki
Nikiforita Poulakaki
APAristea-Maria Papanota
Aristea-Maria Papanota
EKEvgenia Kotsifa
Evgenia Kotsifa
TSTheodoros N. Sergentanis
Theodoros N. Sergentanis
TPTheodora Psaltopoulou
Theodora Psaltopoulou
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory disease that frequently involves the perineal and perianal regions. The association between HS and malignant transformation is a rare but under recognized phenomenon. OBJECTIVE: This systematic review aims to summarize all available cases of vulvar and perianal/perineal cancer emerging in patients with HS, describing clinical and therapeutic particularities of these coexisting conditions in female patients. MATERIALS AND METHODS: This systematic review and pooled analysis was performed in accordance with the PRISMA guidelines; end-of-search date was June 15, 2015. RESULTS: A total of 13 eligible articles were identified; 7 cases of vulvar cancer and 6 cases of perineal/perianal carcinomas in patients with HS were noted. A majority of published cases pertained to rather advanced carcinomas; only occasionally early stage carcinomas were identified. The optimal modifications in the treatment scheme of vulvar, perianal, and perineal cancer in patients with HS have not been established; detailed reporting of recurrence- and survival-related aspects is advised. CONCLUSION: Vulvar, perianal, and perineal cancer represent a rare but serious complication of HS.

1 February 2016 in The Breast
Verified
Journal Article
Closed access
NPNikiforita Poulakaki
Nikiforita Poulakaki
GMGeorgios-Marios Makris
Georgios-Marios Makris
MBMarco-Johannes Battista
Marco-Johannes Battista
DBDaniel Böhm
Daniel Böhm
KPKalliopi Petraki
Kalliopi Petraki
NPNikolaos Papantoniou
Nikolaos Papantoniou

23 January 2014 in Experimental Hematology & Oncology
Verified
Journal Article
Open access
PDF file
AKAnna Koumarianou
Anna Koumarianou
MCMaria-Ioanna Christodoulou
Maria-Ioanna Christodoulou
PPPavlos Patapis
Pavlos Patapis
IPIordanis Papadopoulos
Iordanis Papadopoulos
ELElissavet Liakata
Elissavet Liakata
VPVasiliki Pappa
Vasiliki Pappa
The host’s immune system is crucially involved in cancer development and progression. The ratio of regulatory to effector T-cells, as well as the interplay of T-cells with therapeutic agents, impact on cancer prognosis. The current study aimed to comparatively investigate the effect of metronomic and standard chemotherapy on the number and functionality of peripheral regulatory and effector T-cells in cancer patients.

1 January 2014
Verified
Journal Article
Closed access
DVD Vaidakis
D Vaidakis
TPTheodoros Panoskaltsis
Theodoros Panoskaltsis
NPN Poulakaki
N Poulakaki
AKA Kouloura
A Kouloura
DKD Kassanos
D Kassanos
ESE Salamalekis
E Salamalekis